FCGR3A and neoplasm: Since no studies with trastuzumab as single agent have been published and besides ADCC abrogation of tumor cell signaling being a major effector mechanism of trastuzumab the influence of FcγRIIIa-F158V polymorphism and ADCC on clinical outcome is hard to substantiate.